Great interview & detailed explanation of going from a basic/foundational biological technology platform & pulling in some already established chemistry whose potential is highlighted by the platform, to accelerate into the clinic. $EIKN @EikonTX@bradloncar
Everything you wanted to know about the protein chemistry behind how amino-acid changes affect the cellular abundance of proteins
Effects of residue substitutions on the cellular abundance of proteins
https://t.co/FwoD1kiF30
@andrewwhite01@anshulkundaje I see you give a talk at an AI x DD meeting at the Broad a few years ago and I thought it was fantastic. Almost anti-hype. Gave, ‘listen, we are as shocked as anyone’s how well this stuff works,’ vibes. Been rooting for your company since.
@JasonSynaptic@aemonten Yeah post EM acquisition and mass layoffs, the experience changed dramatically. Even prior to most science twitter folks leaving. There is still a critical mass of great biotech accounts, but for emerging science it is a shadow of what it was.
1/5
Cell identity is written in the proteome, not in the DNA, and not always in the RNA. Out on bioRxiv today: The first cell type-resolved, MS-based proteomic atlas of the human body.
https://t.co/5RJ0nVoQ81
Excited to share our collaborative work with the @TonyMustoe and @SuperSciJew labs, led by the fearless @RitwikaBose15.
In this study, we developed RAID-MAP, an approach to map RNA structure within biomolecular condensates in living cells.
https://t.co/zUeJTnnEMV
Cool new video the Breakthrough Prize team put together featuring Tony @HymanLab and I describing the excitement and adventure of our discovery!
https://t.co/EdPwhG38Of
I prompted the “deep literature” mode of Edison Scientific to write a comprehensive review on the biology of a gene that I know well.
Twenty five min later it sent a 17 page PDF. It was, as best as I can tell, flawless.
Folks, we are not in Kansas anymore.
Don’t at me - try it.
Today we're publishing our index of unmet needs in human disease: 2443 indications scored and ranked on burden of disease, prevalence, pipeline activity, and treatment burden. We hope this will help drug developers identify overlooked medical problems
https://t.co/OX4BKC8cfI